Publications Archive
IP and Collaboration
Chad A. Landmon
Pharmaceutical Executive
March 11, 2021
Interview on the FDA’s Emergency Use Authorization Process for COVID-19 Vaccines
Chad A. Landmon
Pharmacy Times
March 2021
Axinn IP Update: Where is the Federal Circuit Heading in the Skinny Labeling Case?
Chad A. Landmon
Axinn Update
March 4, 2021
Axinn IP Update: Federal Circuit Says Functional Patent Claims Must Clear "High Hurdles"
Stacie L. Ropka, PhD, Aaron Z. Savit, PhD
Axinn Update
February 12, 2021
Axinn IP Update: Federal Circuit Agrees to Reconsider Controversial “Skinny Label” Decision
Chad A. Landmon
Axinn Update
February 10, 2021
Cost and Opportunity in Suspending Early Merger Clearances
Leslie C. Overton, Sam D. Sherman*
Law360
February 8, 2021
Member Spotlight: Francis H. Morrison
Francis Henry Morrison
Voice of Experience
January 27, 2021
The Next Four Years: Antitrust Enforcement on an Upward Trajectory
Lisl J. Dunlop
Concurrences Competition Law Review
January 19, 2021
How President-Elect Biden’s Cabinet Nominations May Impact Pharmacy This Year
Chad A. Landmon
Pharmacy Times
January 15, 2021
Highlights From the OECD Roundtable on the Role of Competition Policy in Promoting Economic Recovery
Caroline Boisvert
Competition Policy International
January 11, 2021
The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
Chad A. Landmon
Contract Pharma
January 5, 2021
If You Can’t Beat Them and You Can’t Join Them: Geisinger-Evangelical’s Warning for Partial Acquisitions
Jeny M. Maier
AHLA PG Briefing
January 4, 2021
Frandly Fire
Thomas K. Hedemann, Ted Mathias
Intellectual Property Magazine, December 2020 / January 2021 Issue
When Japanese Witnesses Testify in U.S. Courts: Answers to Nine Common Concerns
Francis Henry Morrison, Jason Murata
January 2021
Opinion: The Legal and Regulatory Year in Review
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
December 24, 2020
Our Journey to Voting by Mail-In Ballot in North Carolina in 2020
Francis Henry Morrison
Voice of Experience
December 16, 2020
DOJ's 1st Wage-Fixing Indictment is a Warning to Cos.
Tiffany Rider
Law360
December 14, 2020
The U.S. DOJ Indicts a Former Owner of a North Texas Physical Therapist Staffing Company for Conspiring With Competitors to Suppress Wages (Neeraj Jindal)
Tiffany Rider
Concurrences e-Competitions Bulletin
December 9, 2020
Antitrust Treatment of Acceleration Provisions in Hatch-Waxman Settlements
Michael L. Keeley
FDLI’s Update Magazine, Winter 2020 Issue
December 7, 2020
How Justice Barrett’s Confirmation Might Impact Patent Eligibility
Aaron Z. Savit, PhD
World IP Review
December 1, 2020
Top 10 IPR Pitfalls at the Institution Stage
Aziz Burgy
ABA Landslide magazine, Vol. 13, No. 2, November / December 2020 Issue
What the Potential Elimination of the Biologics Price Competition and Innovation Act Means for Pharmacy
Chad A. Landmon
Pharmacy Times
December 1, 2020
Axinn FDA Update: Insights on the MODERN Labeling Act
Chad A. Landmon
Axinn Update
November 20, 2020
Seeking "Mens Sana in Corpore Sano" in a Pandemic
Francis Henry Morrison
Voice of Experience
November 17, 2020
Buyer Beware: Considerations for a Divestiture Buyer in “Litigating the Fix”
Jeny M. Maier
3 Antitrust Report 22, LexisNexis
November 2020
Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge
Chad A. Landmon
The Center for Biosimilars
November 11, 2020
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Leslie C. Overton
GCR Insight: E-Commerce Competition Enforcement Guide
November 2020
The 2020 Axinn Survey of U.S. Litigation Involving Japanese Companies
Rachel J. Adcox, Jason Murata
November 2020
A Look at the Recent DOJ Complaint in U.S. v. Geisinger
Lisl J. Dunlop
AHLA Speaking of Health Law
October 12, 2020
Managing Timing of Multi-Jurisdictional Review
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 2020
What Lemons Teach Us About Privacy and Competition
John D. Harkrider
ABA Antitrust Magazine
Fall 2020
Axinn FDA Update: A Difficult Analysis Is Not Necessarily a Deferential Analysis
Chad A. Landmon
Axinn Update
September 21, 2020
Tuning in to Covered Business Method Review's Series Finale
Eric Krause, Pan Lee
Law360
September 15, 2020
Making It Rain: Rachel Adcox
Rachel J. Adcox
ABA Law Practice Today
August 14, 2020
FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors
Chad A. Landmon
Cell & Gene
August 6, 2020
FDA Informal Guidance Process
Chad A. Landmon
Lexis Practice Advisor
July 30, 2020
Second Circuit: Southern District of New York
Lisl J. Dunlop
GCR Insight: U.S. Courts Annual Review
July 24, 2020
Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
July 21, 2020
Highlights From OECD Roundtable on Conglomerate Mergers
David R. Pearl
Law360
July 13, 2020
Inclusion Matters, Now More Than Ever: Practical Suggestions for Making a Difference
Jason Murata
AIPLA Innovate Magazine
July 10, 2020
Axinn IP Update: District Court Retains Subject Matter Jurisdiction But Grants Dismissal After Paragraph III Conversion
Ricardo Camposanto, Chad A. Landmon, Ted Mathias
Axinn Update
July 8, 2020
Break Up Denny’s
John D. Harkrider
Competition Policy International
July 8, 2020
Assessing the New DOJ, FTC Vertical Merger Guidelines
John D. Harkrider
Law360
July 6, 2020
IPR: The End of the Road for Fifth Amendment Challenges?
Aziz Burgy
World IP Review
July 6, 2020
The U.S. DOJ and FTC Release Their Vertical Merger Guidelines
John D. Harkrider
Concurrences e-Competitions Bulletin
June 30, 2020
Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online / Biosimilar Development
June 23, 2020
Open Source Patent Licenses: Pitfalls and Opportunity
Chad A. Landmon
Bloomberg Law
June 5, 2020
A Lawyer's Guide to Client Service Continuity Planning
Craig M. Reiser, Thomas G. Rohback, Eva Yung
Law360
May 22, 2020
6 Lessons on Jury Advocacy in the Wake of a Crisis
Francis Henry Morrison
Law360
May 11, 2020
ABA SciTech Brief Short Video on COVID-19: FDA Emergency Use Authorizations
Chad A. Landmon
American Bar Association
May 8, 2020
Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
May 4, 2020
Do You Have to Put Up With That? Legal Protections in the Context of Antitrust Law Investigations in the U.S. and E.U.
Nicholas E.O. Gaglio, Lindsey Strang
Compliance Berater
April 28, 2020
Attorney-Client Privilege in the United States: Recent Trends in its Application to Japanese Patent Professionals
Jason Murata
AIPPI Journal
April 2020
A Close Look at European Union's AI Regulation Proposal
Thomas K. Hedemann, Matthew S. Murphy, Brooke J. Oppenheimer
Law360
April 22, 2020
Insulin Under the BPCIA: Opportunities and Obstacles
Ted Mathias, Stacie L. Ropka, PhD
Biosimilar Development
April 22, 2020
FDA’s Emergency Use Authorizations: Aggressive Action Taken to Combat COVID-19
Chad A. Landmon
Contract Pharma
April 20, 2020
Virus Heightens Importance of Drug Shortage Reports to FDA
Chad A. Landmon
Law360
April 2, 2020
FDA Emergency Use Authorizations
Chad A. Landmon
Lexis Practice Advisor Journal
April 1, 2020
The 2019 Axinn Survey of U.S. Litigation Involving Japanese Companies
Rachel J. Adcox, Jason Murata
March 2020
Balancing Settlements, Motions After Fed. Circ. Serta IP Ruling
Stacie L. Ropka, PhD
Law360
March 16, 2020
Navigating Uncertainty in Digital Health Patent Eligibility
Ross E. Blau
Law360
March 2, 2020
Axinn IP Update: Six Patents Directed to Humanized Monoclonal Antibodies Fall at PTAB
Ross E. Blau, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
February 27, 2020
What ACA's Uncertain Future Means for Biologics Patents
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
Law360
February 27, 2020
Chevron’s Hard-Hitting Footnote Nine Revived by Kisor v. Wilkie and Recent Decisions on Deference
Chad A. Landmon
FDLI
February 21, 2020
Axinn IP Update: Settlement Practice in Light of Pending Motions
Stacie L. Ropka, PhD
Axinn Update
February 20, 2020
A Deep Dive Into the Antitrust Claims Against Facebook
Daniel S. Bitton
The Daily Journal
February 14, 2020
Quest Integrity v. Cokebusters Puts Cloud-Based Medical Diagnostic Patents at Risk of On-Sale Bar
Matthew S. Murphy
Medical Device and Diagnostic Industry
February 7, 2020
FDA Administrative Decision Challenges
Chad A. Landmon
Lexis Practice Advisor
January 30, 2020
Pharmaceutical Experience Matters in Defending Pharmaceutical Securities Cases
Matthew J. Becker, Chad A. Landmon
Axinn Update
January 2020
Axinn IP Update: SCOTUS Passes on Refining Subject Matter Eligibility Doctrine
Thomas K. Hedemann
Axinn Update
January 13, 2020
Method of Treatment Eligibility
Aziz Burgy
Intellectual Property Magazine
January 9, 2020
Axinn IP Update: No “Single-Entity” Requirement for Section 271(g) Liability
Ricardo Camposanto, Thomas K. Hedemann
Axinn Update
December 30, 2019
Axinn IP Update: Federal Circuit Addresses BPCIA Safe Harbor, Damages
Ted Mathias, Matthew S. Murphy
Axinn Update
December 19, 2019
Open the Floodgates: The Potential Impact on Litigation Against FDA if the Supreme Court Reverses or Curtails Chevron Deference
Chad A. Landmon
FDLI
December 18, 2019
Who’s Who Legal – Thought Leaders Competition
Daniel S. Bitton, Lisl J. Dunlop, John D. Harkrider
Who’s Who Legal
December 2019
3 Strategies to Manage Case Scope in ANDA Patent Litigation
Aziz Burgy
Law360
December 10, 2019
Little Impact Post-Arthrex for Biologic Patents at the PTAB
Stacie L. Ropka, PhD
The Center for Biosimilars
December 3, 2019
U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?
Chad A. Landmon
IPWatchdog
November 25, 2019
Fed Circ. Ruling May Affect Eligibility of Life Sciences Patents
Ted Mathias
Law360
November 21, 2019
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Leslie C. Overton
GCR Insight: E-Commerce Competition Enforcement Guide
November 20, 2019
Can the FDA Salvage Interchangeable Follow-On Biologics?
Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online / Biosimilar Development
November 19, 2019
Axinn IP Update: Section 287(c) Immunity Has Its Limits
Ross E. Blau, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
November 18, 2019
Curing the Drug Label as Prior Art Malady at the PTAB
Aziz Burgy
IPWatchdog
November 13, 2019
New Calif. Pay-For-Delay Law May Hurt Those It Aims to Help
Chantelle D. Ankerman, Chad A. Landmon
Law360
November 5, 2019
Protecting Intellectual Property in the Era of Intelligent Machines
Thomas K. Hedemann, Matthew S. Murphy
Connecticut Bar Association
Fall 2019
Let Me Ride: No Short-Cuts in the Antitrust Analysis of Ride Hailing
Daniel S. Bitton, David R. Pearl
CLA: Competition, Fall 2019, Vol 29, No. 2
Fall 2019
Axinn IP Update: No Collateral Estoppel after PTAB Ruling on IPR
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
October 9, 2019
Failure to Launch: The Patent Thicket Delay of U.S. Biosimilars
Chantelle D. Ankerman, Ted Mathias, Stacie L. Ropka, PhD
Law360
October 9, 2019
Axinn IP Update: PTAB Abused its Discretion in Denying Patentee Leave to Correct Chain of Priority
Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
October 4, 2019
Managing Timing of Multi-Jurisdictional Review
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 1, 2019
Fed. Circ. Muddies Waters on Method-Of-Treatment Patents
Thomas K. Hedemann
Law360
September 4, 2019
Fixing the Follow-On Insulin Regulatory Approval "Dead Zone"
Chad A. Landmon
BioSimilar Development
September 4, 2019
Axinn IP Update: Federal Circuit Says Method of Treatment Claims Are Not Per Se Eligible Under Section 101
Ross E. Blau, Ted Mathias
Axinn Update
August 29, 2019
Can We Have Mergers Without Tears? Understanding the Basics of Merger Review
Michael L. Keeley
Our Curious Amalgam
August 26, 2019
Recent FDA Court Decision Shows Potential Impact of SCOTUS Deference Decision
Chad A. Landmon
Bloomberg Law and Bloomberg Big Law Business
August 20, 2019
Axinn Insights on U.S. Litigation for Japanese Companies: The Duty to Preserve Documents and Implement Litigation Holds in U.S. Civil Litigation
Rachel J. Adcox, Jason Murata
August 19, 2019
How 2 Recent Court Cases Could Impact Follow-On Biologics Strategy
Stacie L. Ropka, PhD, Aaron Z. Savit, PhD
Biosimilar Development
July 23, 2019
What High Court's Kisor Ruling Means for FDA Decisions
Chad A. Landmon
Law360
July 16, 2019
UnitedHealth-DaVita and Trends in Vertical Merger Enforcement
Jeny M. Maier
AHLA PG Briefing
July 11, 2019
FDA's Aggressive Enforcement Against Stem Cell Companies Starting to Ripen
Chad A. Landmon
Bloomberg BNA Insights
June 27, 2019
How I Made Partner: Jeny Maier
Jeny M. Maier
Law.com
June 19, 2019
Judge Moves Aetna / CVS Deal Into Unchartered Tunney Act Waters
Lisl J. Dunlop, Jeny M. Maier
Bloomberg Law
June 4, 2019
Biologic Labels and Induced Patent Infringement: A Perspective on Evolving U.S. Law
Stacie L. Ropka, PhD
BioProcess International
May 17, 2019
Information Exchange Counseling in the Digital Age
Kail J. Jethmalani
The Antitrust Counselor
May 15, 2019
Axinn IP Update: FDA Issues Final Guidance on Interchangeability of Biologics
Stacie L. Ropka, PhD
Axinn Update
May 14, 2019
Who’s Who Legal – Thought Leaders Competition and Thought Leaders Global Elite
John D. Harkrider
Who’s Who Legal
May 9, 2019
Navigating Vertical Mergers in Healthcare Through a Shifting Enforcement Landscape
Lisl J. Dunlop
Competition Policy International
May 7, 2019
Antitrust Updates from Latin and South America
Kail J. Jethmalani
ABA Section of Antitrust Law
April 26, 2019
The Capitol Forum Thought Leaders Series
Lisl J. Dunlop, Jeny M. Maier
April 25, 2019
Competition in Display Ad Technology: A Retrospective Look at Google / Doubleclick and Google / Admob
Daniel S. Bitton, David R. Pearl
Competition Policy International
April 17, 2019
Justices May Be Ready to Narrowly Overturn 'Auer'
Chad A. Landmon
Law360
March 28, 2019
FDA Doubles Down in Its Updated Biologics Naming Guidance
Chad A. Landmon
The Center for Biosimilars
March 19, 2019
Axinn IP Update: Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals, Inc.
Thomas K. Hedemann, Stacie L. Ropka, PhD
Axinn Update
March 18, 2019
Axinn IP Update: U.S. Supreme Court Holds That Copyright Office Must Grant Copyright Registration Before Infringement Suit Can Be Filed
Rebecca L. Clegg
Axinn Update
March 5, 2019
Status Quo Maintained: FDA Reverses Course on Generic Product Labeling
Chad A. Landmon
FDLI Update
March 1, 2019
Method-of-Treatment Patent Eligibility: Step 1 and Done?
Thomas K. Hedemann
Law360
February 5, 2019
A Hard Choice for Abbreviated Biologics License Applicants
Ted Mathias, Stacie L. Ropka, PhD
Law360
February 4, 2019
Axinn IP Update: Federal Circuit Affirms No Public Use Via Implied Confidentiality
Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
January 30, 2019
Stem Cell Companies Beware: FDA May Come Knocking
Chad A. Landmon
Bloomberg BNA Insights
January 28, 2019
Axinn IP Update: U.S. Supreme Court Ruling Leaves On-Sale Bar Unchanged
Chad A. Landmon, Stacie L. Ropka, PhD
Axinn Update
January 23, 2019
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton
GCR Insight: E-Commerce Competition Enforcement Guide
January 10, 2019
Bringing Light to the DOJ’s Cartel Fine Methodology with the Auto Parts Plea Agreements
Daniel K. Oakes
The Antitrust Bulletin
December 1, 2018
Patent Dance Developments: A Tale of 2 Antibodies
Ted Mathias, Stacie L. Ropka, PhD
Law360
October 26, 2018
Axinn FDA Update: SUPPORT for Patients and Communities Act
Chad A. Landmon
Axinn Update
October 9, 2018
Sports and Labor Monopsonies: Learning from the Pros
Nicholas E.O. Gaglio
ABA Antitrust Law Monopoly Matters (Vol. 16, No. 2)
Fall 2018
Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Second Edition
Chad A. Landmon
ABA: Section of Intellectual Property Law
October 2, 2018
United States: Mergers
Mark D. Alexander
The Antitrust Review of the Americas 2019
September 24, 2018
FDA Focus: What Axinn's Practice Chair Is Watching
Chad A. Landmon
Law360
September 14, 2018
The CRISPR Tug of War
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
IPWatchdog
August 17, 2018
Vertical Healthcare Merger Review After United States v. AT&T, Inc.
Jeny M. Maier
AHLA Weekly
July 27, 2018
Antitrust in the Trump Administration: A Tough Enforcer That Believes in Limited Government
John D. Harkrider
ABA Antitrust Magazine
July 20, 2018
Connecting the Dots: Tracing the DOJ’s Inclusion of Indirect Commerce in Auto Parts Criminal Penalties
Daniel K. Oakes
ABA Antitrust Magazine
July 20, 2018
Integrating Trade Secrets into a Comprehensive IP Strategy
Jason Murata
Today's General Counsel
June 19, 2018
Criminal Antitrust Enforcement Has A New Leader
Tiffany Rider
Law360
May 21, 2018
2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
Ross E. Blau
Westlaw Journal
April 17, 2018
AHLA Antitrust Practice Group Alert
Jeny M. Maier
American Health Lawyers Association
March 27, 2018
Chapter on Non-Prosecutorial Activities
Rachel J. Adcox, Kail J. Jethmalani, Kenina J. Lee
DOJ Civil Antitrust Practice and Procedure Manual
2018
Concentrated Benefits and Dispersed Costs Rent-Seeking by Incumbents Against Innovative and Disruptive Web Based Firms
Daniel S. Bitton, John D. Harkrider
Douglas H. Ginsburg – An Antitrust Professor on the Bench Liber Amicorum Volume 1
March 1, 2018
Navigating the Jurisdiction of American Courts
Daniel S. Bitton, John DeQ. Briggs
February 2018
Unrung Bells and the Quick-Peek Order
Brooke J. Oppenheimer, Thomas G. Rohback
New York Law Journal
February 2, 2018
Re-Designing the American Antitrust Machine Part I: Treble Damages, Contribution and Claim Reduction
John DeQ. Briggs
(published in “Douglas H. Ginsburg, an Antitrust Professor on the Bench,” Liber Amicorum, by the Institute of Competition Law)
2018
Transatlantisch gebruik van verklaringen: medewerkingsplicht in de EU kan leiden tot verboden zelfincriminatie in de VS (Transatlantic use of witness statements: how EU cooperation obligations can lead to violation of the Fifth Amendment)
Daniel S. Bitton
Tijdschrift Mededingingsrecht in de Praktijk
December 2017
President Trump's Long-Awaited FTC Picks: Business as Usual
Kail J. Jethmalani
The Antitrust Counselor
November 2017
Sister Company Liability for Antitrust Conspiracies: Open Questions in Reconciling Copperweld and Twombly
Carol Xianxiao Liu
Perspectives in Antitrust
Fall 2017
Compliance Programs and Leniency Applications in Asian Jurisdictions
Nicholas E.O. Gaglio, Kail J. Jethmalani, Jarod G. Taylor
Cartel & Criminal Practice Committee Newsletter
Fall 2017
United States: Mergers
Mark D. Alexander
The Antitrust Review of the Americas 2018
September 8, 2017
Cyber Ransoms: Mr. Smith Attacks HBO's Loot Train
Brooke J. Oppenheimer, Thomas G. Rohback
New York Law Journal
August 28, 2017
Statutory Damages: The Future of Cybersecurity Litigation
Thomas G. Rohback
Corporate Counsel
March 21, 2017
Developing Trends In Cyberinsurance Litigation
Thomas G. Rohback
Law360
February 13, 2017
Joint Infringement Post-Akamai Part Two: Decisions Since Akamai and Practice Insights
Matthew J. Becker
The Intellectual Property Strategist
February 2017
Joint Infringement Post-Akamai Part One: Exploring the New Joint Infringement Standard
Matthew J. Becker
The Intellectual Property Strategist
January 2017
Standing in Data Breach Cases
Thomas G. Rohback
Today's General Counsel
December 2016
How Much Detail Should You Provide in a Patent Infringement Complaint?
Jason Murata
Intellectual Property Magazine
December 2016
The Future of Insurance Under a Trump Administration
Thomas G. Rohback
Law360
December 2, 2016
Cash Tender Offers Under the HSR Act: Protecting an Efficient Market for Corporate Control
John D. Harkrider
Antitrust Magazine
Fall 2016
Recent Developments in Japanese and U.S. Trade Secret Laws
Jason Murata
Business Law Journal, No. 104
November 2016
Merger Control in the U.S.: Obama’s Legacy
Daniel S. Bitton
Tijdschrift Mededingingsrecht in de Praktijk
October 2016
Concentratiecontrole in China: een terugblik op acht jaar onder de antimonopolie wet (Merger Control in China: Looking Back at Eight Years of Enforcement Under the Anti-Monopoly Law)
Daniel S. Bitton
Tijdschrift Mededingingsrecht in de Praktijk
October 2016
Positive EMA Opinions Could Bode Well For US Approvals of Biosimilars
Stacie L. Ropka, PhD
The Pharma Letter
September 7, 2016
It’s Your Party, And You Can Dance If You Want To
Stacie L. Ropka, PhD
Life Sciences Intellectual Property Review
August 23, 2016
After-Developed Defenses Still Relevant After Halo
Ted Mathias, Matthew S. Murphy
Law360
July 15, 2016
Limits of Cyber Insurance Being Tested in Litigation
Thomas G. Rohback
Today’s General Counsel
June 2016
It’s My Party v. Live Nation
Kail J. Jethmalani
American Bar Association Young Lawyers Division Antitrust Committee Newsletter
Spring 2016
The Next AIA Battleground: IPR And Estoppel
Jason Murata
Law360
May 26, 2016
Spokeo’s Impact on Data Breach Cases: The Class Action Floodgates Have Not Been Opened, But the Door Has Not Been Locked
Thomas G. Rohback
The Cybersecurity Law Report
May 25, 2016
When Do Consumers Have Standing to Sue Over Data Breaches?
Thomas G. Rohback
The Cybersecurity Law Report
May 11, 2016
No Safe Harbor: The Effect of the Schrems Decision on Cross-Border Discovery
Kenina J. Lee, Brooke J. Oppenheimer
Competition Torts News
March 15, 2016
Working the Clock: Strategic Choices in Managing Global Regulatory Review Timelines
John D. Harkrider, Kail J. Jethmalani
The Antitrust Counselor
March 15, 2016
How 3 Agencies Prosecute Lax Cybersecurity
Thomas G. Rohback
Law360
March 2, 2016
Data Analytics to Identify Hot Spots in Obviousness Challenges
Ricardo Camposanto
Inside Counsel
February 29, 2016
The Supreme Court Restricts Antitrust State Action Immunity
Richard B. Dagen
Corporate Counsel
December 2015
Heisenberg’s Uncertainty Principle, Extraterritoriality and Comity
Daniel S. Bitton, John DeQ. Briggs
Fall 2015
Cybersecurity Litigation: The Tip of the Iceberg
Thomas G. Rohback
InsideCounsel
Fall 2015
Using FDA’s Citizen Petition Process and Litigation to Achieve Market Success
Chad A. Landmon
Biotechnology Law Report
October 2015
Section 101 Requires Something More . . . But How Much More?
Ted Mathias
The Report
Fall 2015
Media General, Meredith Looking To Make Swaps
Daniel S. Bitton
The Deal
September 9, 2015
FDA Regulation of HCT/Ps – Impact of New Guidances on Manufacturers and Users
Chad A. Landmon, Stacie L. Ropka, PhD
GxP Lifeline
August 2015
John Harkrider Interviewed Director of Competition of the FTC
John D. Harkrider
MLex
June 25, 2015
Counsel’s Corner: Smart Approach to FDA May Lead to Faster Decisions, Savings
Chad A. Landmon
Bloomberg BNA Pharmaceutical Law & Industry Report
June 12, 2015
Tempest in a Teapot: Gilead v. Natco Is No Sea Change in the Doctrine of Obviousness-Type Double Patenting
Thomas K. Hedemann
Spring 2015
FDA's First Biosimilar Approval Greeted with Optimism; Naming, Pricing Still Issues
Stacie L. Ropka, PhD
Bloomberg BNA Life Science’s Law & Industry Report
March 9, 2015
FDA Approves First US Biosimilar from Sandoz
Stacie L. Ropka, PhD
BioPharma-Reporter.com
March 6, 2015
Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
Stacie L. Ropka, PhD
The Pink Sheet
March 6, 2015
FTC Smiling as High Court Rules Dental Board Lacks Antitrust Immunity
Richard B. Dagen
Bloomberg BNA
March 3, 2015
Ranbaxy Loses Bid to Block Other Firms' Nexium, Valcyte Generic Products
Chad A. Landmon
Bloomberg BNA Pharmaceutical Law & Industry Report
March 2, 2015
U.S. FDA Postpones Celltrion's Remicade Biosimilar Review Meeting
Stacie L. Ropka, PhD
BioPharma Reporter.com
February 27, 2015
Supreme Court: State Dental Board Not Immune From Antitrust Laws
Richard B. Dagen
Global Competition Review
February 26, 2015
NC Dental Gives State Boards Map To Avoid Antitrust Trouble
Richard B. Dagen
Law360
February 25, 2015
Supreme Court Conservatives Split Over Antitrust Scrutiny of State Boards
Richard B. Dagen
Forbes
February 25, 2015
A Call for Antibody Quality Control
Stacie L. Ropka, PhD
BioPharm International
February 18, 2015
FTC Wins Hospital Merger Appeal in Ninth Circuit
Richard B. Dagen
Global Competition Review
February 11, 2015
Staples Agrees to Buy Office Depot, FTC Approval Seen Likely
Michael L. Keeley
Reuters
February 4, 2015
Staples and Office Depot Say a Merger Will Keep Them Competitive
Michael L. Keeley
The New York Times
February 4, 2015
FTC May Eye Corporate Sales In A Staples-Office Depot Deal
Michael L. Keeley
Law360
February 3, 2015
Staples, Office Depot Expect Second Time a Charm in Merger
Michael L. Keeley
Reuters
February 3, 2015
Dollar General Cites Regulatory Hurdles to Bid for Family Dollar
Michael L. Keeley
The Wall Street Journal
January 22, 2015
Starboard Asks Staples to Merge with Office Depot
Michael L. Keeley
Reuters
January 20, 2015
Dollar General Hits Do-Or-Die Point In $9B Hunt For Rival
Michael L. Keeley
Law360
January 13, 2015
Patents Are Back as Top Issue for 2015, Life Sciences Attorneys Say
Stacie L. Ropka, PhD
Bloomberg BNA Life Sciences Law & Industry Report
January 9, 2015
5 Lessons We Can Learn from FDA’s First Biosimilar Review
Stacie L. Ropka, PhD
Law360
January 8, 2015
Twombly, Iqbal And The Demise Of Form 18
Jason Murata
Law360
November 18, 2014
Schrödinger’s Cat and Extraterritoriality
John DeQ. Briggs
Antitrust Magazine
Fall 2014
ANDA Litigation: Patents Are Being Challenged Sooner, OxyContin Draws Most Fire
Chad A. Landmon
The Pink Sheet
November 6, 2014
That Argument Don’t Hunt
Richard B. Dagen
ABA Antitrust Law Section’s Cartel and Joint Conduct Review
Fall 2014
Reflections on the Supreme Court and State Action Immunity
Richard B. Dagen
Global Competition Review
October 24, 2014
Copaxone Supreme Court Case Could Cut Relitigation of Patent Claims
Chad A. Landmon
The Pink Sheet
October 13, 2014
Ford, GM Argue They Don’t Owe Any Music Royalties
Richard B. Dagen
The National Law Journal
October 13, 2014
Iraq Asks 2nd Circ. For $10B Oil-For-Food Rehearing
John D. Harkrider
Law360
October 3, 2014
Judge Rebuffs Antitrust Claims Against Canadian Maker of Therapy Products
Russell M. Steinthal
Global Competition Review
October 1, 2014
Family Dollar FTC Antitrust Concerns Supported by Pricing Study
Michael L. Keeley
Bloomberg
September 17, 2014
FTC Acknowledges Auto Dealer Probe After Discovery Bust-Up
Richard B. Dagen
Global Competition Review
September 16, 2014
Rule Against Double Patenting Regains Lost Luster
Thomas K. Hedemann
The National Law Journal
September 8, 2014
Bidding War Breaks Out to Dominate Dollar Stores
Michael L. Keeley
The Wall Street Journal
August 18, 2014
Dollar General / Family Dollar a Tougher Antitrust Sell, Observers Say
Michael L. Keeley
Global Competition Review
August 18, 2014
Biosimilar Firms Must Be Ready for US ‘Patent Dance,’ Says IP Lawyer
Stacie L. Ropka, PhD
BioPharma-Reporter.com
August 13, 2014
Valeant effort may require more divestitures
Richard B. Dagen
Global Competition Review
August 13, 2014
NCAA Ruling Clears Path For More Antitrust, Labor Brawls
Russell M. Steinthal
Law360
August 11, 2014
Invitations to Collude: An Offer You Can Refuse
Richard B. Dagen
Global Competition Review
August 1, 2014
Alienage Suit In NY Presages New Wave Of Employment Claims
Thomas G. Rohback
Law360
July 14, 2014
BIO, PhRMA Ask Fed. Circ. To Revisit Double-Patent Ruling
Thomas K. Hedemann
Law360
July 14, 2014
FTC Economist: Big Data Only One Factor for Online Success
Daniel S. Bitton
Global Competition Review
June 11, 2014
Are Your Secrets Safe?
Jason Murata, Brooke J. Oppenheimer
Risk Management
June 1, 2014
Protecting Business Trade Secrets When Working Abroad
Jason Murata
Hartford Business Journal
April 28, 2014
IP Law: Trade Secrets And Patent Reform
Jason Murata
The Connecticut Law Tribune
April 17, 2014
U.S. Clears Facebook / WhatsApp With Warning Over Privacy
Daniel S. Bitton
Global Competition Review
April 11, 2014
Wright Calls for Equal Burdens of Proof in Ardagh Dissent
Daniel S. Bitton
Global Competition Review
April 4, 2014
Seeing the Forest Through The SEPs
John D. Harkrider
Antitrust Magazine
March 25, 2014
Price signaling krijgt hernieuwde aandacht van handhavers in EU en VS (Price Signaling Attracting Attention from Enforcers in the E.U. and U.S.)
Daniel S. Bitton
Tijdschrift Mededingingsrecht in de Praktijk
March 2014
Supreme Court will hear North Carolina Dental appeal
Richard B. Dagen
Global Competition Review
March 3, 2014
Eurotunnel and the Short Sea Battle Between the French and the English: A U.S. Perspective
John DeQ. Briggs, Daniel K. Oakes
Revue Concurrences N° 1-2014, Art. N° 62589 (with Daniel K. Oakes)
February 2014
Jos A Bank could use FTC review to scupper takeover
Daniel S. Bitton, Richard B. Dagen
Global Competition Review
February 5, 2014
St Luke’s merger decision will be tough to overturn, observers say
Richard B. Dagen
Global Competition Review
January 29, 2014
Gilead Could Move to Bundle Recent Idenix Patent Disputes, Likely to Hinge on Issues of Prior Art, Invalidity – Attorneys
Chad A. Landmon
BioPharm Insight
January 5, 2014
Antitrust Agencies Update U.S. Model Antitrust Confidentiality Waiver
December 9, 2013
FDA Announces Major Generic Drug Labeling Changes In the Wake of Preemption Decisions Involving Generic Drug Product Liability
Chad A. Landmon
Corporate Compliance Insights
November 21, 2013
Should The Entire Market Value Rule Apply To Lost Profits?
Ted Mathias, Matthew S. Murphy
Law360
November 5, 2013
In Focus: Drug Sponsor and Contractor Relations
Chad A. Landmon
November 4, 2013
REPs Not SEPs
October 15, 2013
Obviousness in Medical Device Patent Litigation
Jason Murata
Corporate Counsel
September 16, 2013
Scientific Speech Highlighted In SCOTUS Petition To Overturn CEO Conviction
Chad A. Landmon
Inside Health Reform
August 21, 2013
Imperiled SAC Shifts To Plan B: Protecting Its Wallet
Thomas G. Rohback
July 26, 2013
Law360's Q&A With Axinn's Matthew Becker
Matthew J. Becker
Law360
July 15, 2013
"Reliance" in Class Actions Clarified by Supreme Court
Thomas G. Rohback
Today's General Counsel
July 1, 2013
FTC to Launch Broad Study of "Patent Trolls"
Russell M. Steinthal
June 20, 2013
Attorneys React to High Court's Gene Patent Ruling
Chad A. Landmon
Law360
June 13, 2013
Supreme Court Continues To Tackle Class Actions
Thomas G. Rohback
Law360
June 3, 2013
Inching Toward Balance: Reaching Proper Reform of the Alaska Native Corporations
Daniel K. Oakes
Contracting Preferences
Spring 2013
John Harkrider and Team Featured in The American Lawyer’s ‘Big Suits’ Column
John D. Harkrider
The American Lawyer
February 27, 2013
Thomas Rohback Interviewed for Financier Worldwide's 2013 Annual Review
Thomas G. Rohback
Financier Worldwide
February 22, 2013
Satisfying the "Meet and Confer" Requirement in Federal Court
Nicholas E.O. Gaglio
Pretrial Practice & Discovery
January 28, 2013
2012 Court Decisions Impact the Life Science Industry
Chad A. Landmon
Pharmaceutical Compliance Monitor
January 3, 2013
Closing at Your Peril: Post-Consummation Merger Challenges
Rachel J. Adcox, John D. Harkrider
The Threshold
Summer 2012
Getting Your Best Outcome Post-AU Optronics: Pay No Attention to That Case Behind The Curtain
Rachel J. Adcox
Antitrust
July 24, 2012
Growing Pains: The Seagate Standard After Powell v. Home Depot
Ted Mathias, Stacie L. Ropka, PhD
April 5, 2012
Use of License Agreements to Determine Reasonable Royalties
Ted Mathias
March 30, 2012
Brand's Off-Label Promotion: Valuable Tool for Generics
Thomas K. Hedemann
Law360
December 31, 2011
When the Case Is Over: A Tunney Act Primer for Defendants
Rachel J. Adcox
ABA, Young Lawyers
December 31, 2011
An Inherent Conflict Between WTO Law and a Sustainable Future? Evaluating the Consistency of Canadian and Chinese Renewable Energy Policies with WTO Trade Law
Kenina J. Lee
Georgetown International Environmental Law Review
2011
Axinn Partner Michael Keeley Speaks To Reuters on NBA Antitrust Lawsuit
Michael L. Keeley
November 3, 2011
Innovative Procedures v. Premarketing Approval
Chad A. Landmon
Law360
September 20, 2011
Machine-Or-Transformation Test After Myriad: Implications To The Prosecution Of Process Claims
Stacie L. Ropka, PhD
Patent Law Practice Center
August 15, 2011
Heightened Standard For The Entire Market Value Rule?
Ted Mathias
Law360
August 3, 2011
Durbin Amendment Rules To Pare "Anticompetitive" Debit Card Interchange Fees
Mark D. Alexander
ABA, Section of Antitrust Law
Spring 2011
Human Tissue and Stem Cell Therapies: Revolutionary New Therapies that Face Increasing FDA Scrutiny
Chad A. Landmon
FDLI Update
September 30, 2010
Questions Unanswered in Work Product Protection
Nicholas E.O. Gaglio
Law360
August 10, 2010
Obama: The First Year
John D. Harkrider
ANTITRUST
Summer 2010
Supreme Court Puts Brakes on Expansive Single-Entity Treatment for Joint Ventures
May 26, 2010
FTC Issues Authorized Generics Report
July 8, 2009
Head of the DOJ's Antitrust Division Outlines the Agencies' Plans to Reinvigorate Antitrust Enforcement
May 14, 2009
Lessons from the Great Depression
John D. Harkrider
ANTITRUST
April 1, 2009
Trends in FTC Merger Enforcement: Assessing the Most Recent Data
Michael L. Keeley, Russell M. Steinthal
The Threshold
Spring 2009
Federal Circuit Draws the Line on DJ Jurisdiction
Chad A. Landmon
Law360
August 25, 2008
FTC Wins Significant D.C. Circuit Reversal in Whole Foods / Wild Oats Merger Challenge
August 1, 2008
Antitrust Enforcement During the Bush Administration
John D. Harkrider
ANTITRUST
July 1, 2008
FDA's Exclusivity Forfeiture Saga Continues
Chad A. Landmon
IP Law360
May 15, 2008
Raising the Bar of Patentability
Matthew J. Becker, Thomas K. Hedemann
Connecticut Law Tribune
April 21, 2008
Here Comes The Tidal Wave of Generic DJ Actions
Chad A. Landmon
IP Law360
April 3, 2008
FDA Removes Teeth From Exclusivity Forfeiture
Chad A. Landmon
IP Law360
January 25, 2008
Mike Keeley in Reuters: "Most presidential hopefuls antitrust moderates"
Michael L. Keeley
January 13, 2008
Doe v. Norwalk Community College Analysis for LexisNexis Expert Commentaries
November 2007
What is Patentable?
Matthew J. Becker, Thomas K. Hedemann
IP Law and Business
October 2007
Supreme Court Overturns Century-Old Precedent; Allows Rule of Reason Treatment for Minimum Resale-Price-Maintenance Agreements
July 2, 2007
Supreme Court Backhands Key Federal Circuit Test
Chad A. Landmon
IP Law360
January 10, 2007

View Current Publications ›

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.